PrescQIPP

High cost drugs

All our resources relating to high cost drugs, plus links to national resources. This will include resources that cover some of the general principles and issues relating to implementation of biosimilars.

Bulletin 309: Commissioning of high cost drugs and devices

Read more > >

B264: Subcutaneous infliximab

This bulletin reviews the place in therapy for subcutaneous Infliximab which may help reduce capacity problems with providers during the current pandemic. A cost calculator tool template is available as a supporting resource.

View >>

B274: Subcutaneous vedolizumab

Reviews the place in therapy for subcutaneous vedolizumab which may help reduce capacity problems with providers during the current pandemic. A cost calculator tool template is available as a supporting resource.

View >>

Biologics cost calculator

The Biologics cost calculator is a tool to compare costs for biologic agents used in different diseases states, taking into account local drug acquisition cost and associated activity charges. Disease states currently covered include:

  • Rheumatoid arthritis
  • Ulcerative colitis
  • Crohn's disease
  • Axial spondyloarthritis
  • Plaque psoriasis
  • Psoriatic arthritis
  • Atopic dermatitis

View >>

Visual FP10 High cost drugs and high risk drugs prescribing report

This PrescQIPP report has been designed to allow the identification of inappropriate prescribing of both high cost drugs excluded from the National Tariff, and drugs which are associated with a high risk and therefore may not be suitable for prescribing in primary care.

The report has been run on all high cost drugs excluded from the National Tariff and cytotoxic agents from sections 8.1 and 8.2 of the BNF.

View >>

Our regular virtual meeting brings together subscribers with a shared interest in high cost drugs and biosimilars to discuss issues, challenges and experiences. 

Find out more and sign up here